In December 2011, the Abramson Cancer Center released a request for applications to the Penn Community for Translational Centers of Excellence (TCEs). The purpose of this initiative is to catalyze the formation of interdisciplinary groups of scientists and clinicians who propose translational approaches to the prevention and treatment of specific forms of cancer.
Eight TCE applications were submitted. All were evaluated by a peer review committee of scientific advisors external to the University of Pennsylvania. Selected TCEs were then invited to present proposals to an internal advisory board composed of Department Chairs and Center and Institute Directors.
We are pleased to inform you that two TCEs have been selected for funding:
The 2-PREVENT TCE, led by Lewis Chodosh, MD, PhD and Angela DeMichele, MD, will pursue innovative, transdisciplinary approaches to the prediction, prevention, monitoring, detection and treatment of recurrent breast cancer.
The Hematologic Malignancies/Leukemia TCE, led by Martin Carroll, MD and Edward Stadtmauer, MD, seeks to re-define the diagnostic and therapeutic approach to blood cancers in order to
provide more effective targeted therapies.
Details about the funded TCEs will be posted soon on the Abramson Cancer Center website. All other TCE applicants are now considered TCEs of the ACC. These emergent TCEs are in developmental form, and in some cases limited strategic funding will be invested so that these TCEs will reach their full potential in future funding cycles. The ACC will release another request for TCE applications in December 2012.
We are incredibly proud of and excited by the quality of all the TCE applications that were submitted. This process has, as we hoped, served as a mechanism to bring together some incredible new Penn teams with innovative ideas in translational research.
We are looking forward to great things.
Chi Van Dang, MD, PhD
Director, Abramson Cancer Center
Caryn Lerman, PhD
Deputy Director, Abramson Cancer Center